⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56377 | 1.00 | — | — | |
| Cyanide SCHEMBL15661517 | 0.93 | ALOX15 (0.39) | — | |
| SCHEMBL3603740 | 0.85 | ALOX15 (0.40) | — | |
| SCHEMBL31713015 | 0.83 | ALOX15 (0.39) | — | |
| Charcoal, Activated SCHEMBL31304029 | 0.83 | ALOX15 (0.39) | — | |
| SCHEMBL5474126 | 0.78 | ALOX15 (0.48) | — | |
| SCHEMBL5464714 | 0.78 | AHR (0.48) | — | |
| SCHEMBL209619 | 0.75 | HTR2C (0.48) | — | |
| SCHEMBL30390513 | 0.75 | — | — | |
| SCHEMBL29603326 | 0.75 | HTR2C (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231340-A8 | AZAINDOLE AND AZAINDOLINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-12-11 | — | — | WO | disclosed |
| WO-2025231340-A1 | AZAINDOLE AND AZAINDOLINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025073792-A1 | WRN INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| US-20250026722-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Université Côte d’Azur (FR) | 2025-01-23 | — | — | US | disclosed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| EP-4399202-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230381232-A1 | METHODS AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-11-30 | — | — | US | disclosed |
| WO-2023072962-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2023-05-04 | — | — | WO | disclosed |
| EP-4169904-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2023-04-26 | — | — | EP | disclosed |
| US-20230113944-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-11564947-B2 | Methods and compositions for cellular immunotherapy | Effector Therapeutics Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220378821-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-01 | — | — | US | disclosed |
| EP-4087847-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | The Regents of the University of California (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3288921-B1 | POLYCYCLIC INDOLINE AND INDOLENINE COMPOUNDS | UNIV COLORADO REGENTS (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3993875-A1 | METHODS OF TREATING BRAF-MUTATED CANCER CELLS | EFFECTOR THERAPEUTICS, INC. (US) | 2022-05-11 | — | — | EP | disclosed |